Can post-ERCP acute pancreatitis be predicted and prevented;Question n° 6: Peut-on prévoir et prévenir la pancréatite aiguë post-cholangio-pancréatographie rétrograde endoscopique?

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 1 SUPPL., 2001, Pages

  Hastier, P ^a  

^a NONE   (France)

Author keywords

Acute pancreatitis; ERCP; Prevention; Treatment

Indexed keywords

ALLOPURINOL; AMYLASE; APROTININ; CALCITONIN; CORTICOSTEROID; GABEXATE; GLUCAGON; HEPARIN; METHYLPREDNISOLONE; NIFEDIPINE; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; STEROID; CONTRAST MEDIUM; SERINE PROTEINASE INHIBITOR; SOMATOSTATIN; IONIC CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM;

ACUTE PANCREATITIS; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; ENDOSCOPIC THERAPY; HUMAN; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; MANOMETRY; PANCREATITIS; PANCREATOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ACUTE DISEASE; CONSENSUS DEVELOPMENT; AGE; FEMALE; MALE; REVIEW; SEX DIFFERENCE; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CONTRAST MEDIA; GABEXATE; HUMANS; OCTREOTIDE; PANCREATITIS; SERINE PROTEINASE INHIBITORS; SOMATOSTATIN; AGE FACTORS; FEMALE; MALE; RISK FACTORS; SEX FACTORS;

EID: 0035095015     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (122)

1. Toward improving outcomes of ERCP
2. Severe and fatal complications after diagnostic and therapeutic ERCP: A prospective series of claims to insurance covering public hospitals
3. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes
4. Hyperamylasemia and acute pancreatitis following ERCP
5. Hyperamylasemia after duodenoscopy and retrograde cholangiopancreatography
6. Diagnosis and prevention of post-ERCP pancreatitis
7. Post-ERCP pancreatitis: Randomized, prospective study comparing a low-and high-osmolality contrast agent
8. Complications of endoscopic biliary sphincterotomy
9. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography
10. Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis
11. Endoscopic sphincterotomy complications and their management: An attempt at consensus
12. ERCP and endoscopic biliary sphincterotomy induced pancreatitis
13. A prospective study of the safety of endoscopic therapy for choledocholithiasis in an outpatient population
14. Complications of endoscopic biliary sphincterotomy: A review
15. Les essais thérapeutiques randomisés dans le traitement de la pancréatite aiguë
16. Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study
17. Urinary trypsinogen-2 test strip in detecting ERCP-induced pancreatitis
18. Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis
19. Twenty four hour serum amylase predicting pancreatic reaction after endoscopic sphincterotomy
20. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis
21. ERCP and endoscopic sphincterotomy induced pancreatitis
22. Acute pancreatitis following gastrointestinal endoscopy without ampullary cannulation
23. Acute pancreatitis following endoscopic retrograde cholangiopancreatography
24. Complications of endoscopic sphincterotomy: A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and non dilated bile ducts
25. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study
26. Risk factors for post-ERCP pancreatitis: A multivariate analysis of 1427 cases
27. Is post-ERCP acute pancreatitis predictable? A prospective study
28. Evaluation of post-ERCP pancreatitis: Potential causes noted during controlled study of differing contrast media
29. Predictors of post-ERCP complications in patients with suspected choledocholithiasis
30. Changes in serum levels of pancreatic isoamylase, lipase, trypsin, and elastase 1 after endoscopic retrograde pancreatography
31. Manometric endoscopic retrograde pancreatography: Technique, significance and evaluation
32. Contrast absorption and pancreatic inflammation following experimental ERCP
33. Demonstration of pancreatic parenchyma by digital subtraction techniques during endoscopic retrograde cholangiopancreatography
34. Post-ERCP pancreatitis: Association with urographic visualisation during ERCP
35. A randomized prospective study comparing two contrast media in ERCP
36. Complications of endoscopic sphincterotomy and their prevention
37. Papillary roof incision using the Erlangen-type pre-cut papillotome to achieve bile duct cannulation
38. Pre-cut papillotomy
39. Needle-knife sphincterotomy as a pre-cut procedure - A retrospective evaluation of efficacy and complications
40. Needle-knife sphincterotomy in a tertiary referral center: Efficacy and complications
41. Post-ERCP pancreatitis and hyperamylasemia: The role of operative and patient factors
42. A prospective assessment of results for needle-knife sphincterotomy and standard endoscopic sphincterotomy
43. Endoscopic papillotomy
44. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current
45. Morphology of the pancreatic ductal epithelium after traumatization of the papilla of Vater or endoscopic retrograde pancreatography with contrast media in cats
46. The immediate effects of retrograde pancreatography on the pancreas
47. A comparison of a new non-ionic (metrizamide) and a dissociable (metrizoate) contrast medium in endoscopic retrogade pancreatography (ERP)
48. Iopamidol as contrast medium in endoscopic retrograde pancreatography: A prospective randomised comparison with diatrizoate
49. A comparative study of contrast agents for endoscopic retrograde pancreatography
50. A trial of low osmolar versus high osmolar contrast media in ERCP
51. Metrizamide as contrast medium in endoscopic retrograde cholangiopancreatography
52. Hyperamylasemia after ERCP with ionic and non-ionic contrast media
53. A randomized trial of iohexol versus amidotrizoate in endoscopic retrograde pancreatography
54. A comparison of nonionic versus ionic contrast media: Results of a prospective multicenter study
55. The internationnal workshop on the sphincter of Oddi manometry
56. Sphincter of Oddi manometry: Decreased risk of clinical pancreatitis with use of a modified aspirating catheter
57. Pancreatitis following bile duct sphincter of Oddi manometry: Utility of the aspirating catheter
58. Pancreatitis after sphincter of Oddi manometry
59. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM)
60. Prospective evaluation of the risk of bacteriema and the role of antibiotics in ERCP
61. Bacteremia following diagnostic and therapeutic ERCP
62. The value of prophylactic antibiotic therapy during endoscopic retrograde cholangiopancreatography
63. Meta-analysis of antibiotic prophylaxis in endoscopic cholangiopancreatography (ERCP)
64. Analysis of the risks factors associated with endoscopic sphincterotomy techniques: Preliminary reports of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment
65. Are complications of endoscopic sphincterotomy age related?
66. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients
67. Sphincter of Oddi dysfunction: Results of treatment by endoscopic sphincterotomy
68. Endoscopic sphincterotomy-induced pancreatitis: Increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction
69. Long-term outcome after endoscopic sphincterotomy in patients with biliary colic and suspected sphincter of Oddi dysfunction
70. Endoscopic sphincterotomy for suspected dysfunction of the sphincter of Oddi
71. Successes, failures, early complications and their management following endoscopic sphincterotomy: Results in 394 consecutive patients from a single centre
72. Clinical outcome of post-ERCP pancreatitis: Relationship to history of previous pancreatitis
73. Endoscopic papillotomy for common bile duct stones: Factors influencing the complication rate
74. Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques
75. Endoscopic sphincterotomy for stones by expert is safe, even in younger patients with normal ducts
76. Endoscopic retrograde cholangiopancreatography: Toward a better understanding of competence
77. Assessment of technical competence during ERCP training
78. Quantative assessment of procedural competence. A prospective study of training in endoscopic retrograde cholangiopancreatography
79. The role of glucagon in endoscopic cholangiopancreatography
80. Prospective study for the prevention of pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP)
81. A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography
82. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography
83. Prospective randomized trial of the effect of nifedipine on panceatic irritation after endoscopic retrograde cholangiopancreatography
84. Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis in a canine model
85. Use of corticosteroids in the prevention of post-ERCP pancreatitis
86. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: A randomized, multicenter, placebo-controlled clinical trial
87. Use of corticosteroids in the prevention of post-ERCP pancreatitis: Results of a controlled prospective study
88. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis
89. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rats
90. Prevention of the pread of experimental acute pancreatitis by intraductal administration of a synthetic inhibitor in dogs
91. Effectiveness of gabexate in acute pancreatitis. A meta-analysis
92. Rewiev article: The relative effectiveness of somatostatin and octreotide therapy in pancreatic disease
93. Somatostatin therapy of acute experimental pancreatitis
94. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rats
95. Action of somatostatin on sphincter d'Oddi in vivo: Inter-relations of somatostatin-cholecystokinin
96. The effects of somatostatin and octreotide on the human sphincter of Oddi
97. Effects of somatostatin on clinical, biochemical and morphological changes following ERCP
98. Effect of somatostatin on hyperamylasemia following endoscopic pancreatography
99. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy
100. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study
101. Can somatostatin prevent injection pancreatitis after ERCP?
102. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: Results of a randomized study
103. Prophylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial
104. Endoscopic papillosphincterotomy: Prevention of pancreatic reaction by somatostatin
105. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis
106. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography
107. A multicenter, randomized, controled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis
108. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?
109. The use of long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy
110. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy
111. Long term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla
112. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography
113. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP
114. Effect of somatostatin analog octreotide on human sphincter of Oddi
115. Meta-analysis of somatostatin, octreotide, and gabexate mesilate in the therapy of acute pancreatitis
116. Endoscopic pancreatic sphincterotomy: Indications, outcome, and a safe stentless technique
117. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-induced pancreatitis? A final analysis of a randomized prospective study
118. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction
119. Does stanting after pancreatic sphincterotomy reduce post-ERCP pancreatitis in patients with prior biliary sphincterotomy? Preliminary results of a prospective randomized trial
120. Magnetic resonance cholangiopancreatography
121. Diagnosis of choledocholithiasis by endoscopic ultrasonography
122. Prospective evaluation of endoscopic ultrasonography and microscopic examination of duodenal bile in the diagnosis of cholecystolithiasis in 45 patients with normal conventional ultrasonogaphy